LXRX Lexicon Pharmaceuticals
- 1.740
- +0.040+2.35%
- 1.750
- +0.010+0.57%
Lexicon Pharmaceuticals News
Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Lexicon Pharmaceuticals (LXRX)
Optimistic Buy Rating for Lexicon Pharmaceuticals Amid Strong Inpefa Sales Outlook and Efficient Financial Management
Needham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns With EPS Projections Amidst Strategic ...
Express News | Lexicon Pharmaceuticals Inc - as of March 31, 2024, Lexicon Had $355.6 Million in Cash and Investments
Express News | Lexicon Pharmaceuticals Inc - Revenues for First Quarter of 2024 Were $1.1 Million, Primarily From the Commercialization of Inpefa
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, Vs. Street Est of $1.4M
04:27 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M
Lexicon Pharmaceuticals Q1 2024 GAAP EPS $(0.20), Inline, Sales $1.130M Miss $1.401M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 17.65 percent decrease over losses of $(0.17) per share from th
Express News | Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Express News | Lexicon Pharmaceuticals Q1 Operating Income USD -45.333 Million
Express News | Lexicon Pharmaceuticals Q1 Basic EPS USD -0.2
Express News | Lexicon Pharmaceuticals Q1 Net Income USD -48.397 Million
Express News | Lexicon Pharmaceuticals Q1 Operating Expenses USD 46.463 Million
Press Release: Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Commercial launch of INPEFA(R) (sotagliflozin) for Heart Failure continues to progress Resubmission
Lexicon Pharma 1Q Rev $1.13M >LXRX
Lexicon Pharma 1Q Rev $1.13M >LXRX
Lexicon Pharma Initiated at Outperform by Leerink Partners
Lexicon Pharma Initiated at Outperform by Leerink Partners
Lexicon Pharmaceuticals: A Buy Rating on Strong Market Prospects and Innovative Pipeline
Express News | Lexicon Pharmaceuticals Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $5
Express News | Lexicon Pharmaceuticals CEO Lonnel Coats Retires
Analysis
Price Target
No Data
